ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology
October 12 2017 - 7:00AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
focused on developing gene and cell-based immunotherapies for
cancer, today announced that three abstracts highlighting data from
the Company’s Ad-RTS-hIL-12 + veledimex program have been accepted
for presentation at the 22nd Annual Meeting and Education Day of
the Society for Neuro-Oncology (SNO). The meeting will be held Nov.
16 - 19 in San Francisco. Additional information will be available
from the Society when all abstracts are released from embargo on
Nov. 6.
Details for the SNO presentations with
discussion are as follows:
E-Talk: A Phase 1 study of
Ad-RTS-hIL-12 + veledimex in adult recurrent glioblastoma
Presenter: E. Antonio Chiocca, M.D., Ph.D.
Session Title: Adult Therapeutics Date and
Time: Saturday, Nov. 18, 5:32 – 5:36 p.m. PST
Abstract Code: ATIM-26
Oral Presentation: Controlled
expression of IL-12 improves survival in glioma by activating the
immune response in mice and humansPresenter: John
A. Barrett, Ph.D. Session Title: Immunology –
Preclinical and Clinical IDate and Time: Sunday,
Nov. 19, 9:15 - 9:20 a.m. PST Abstract Code:
IMMU-34
Oral Presentation: Controlled
local expression of IL-12 as gene therapy concomitant with systemic
chemotherapy improves survival in gliomaPresenter:
John A. Barrett, Ph.D.Session Title: Immunology –
Preclinical and Clinical I Date and Time: Sunday,
Nov. 19, 10 - 10:05 a.m. PST Abstract Code:
IMMU-33
About Ad-RTS-hIL-12 plus Veledimex
ZIOPHARM is advancing Ad-RTS-hIL-12 plus
veledimex as a gene therapy for glioblastoma. Ad-RTS-hIL-12 is an
adenoviral vector administered via a single injection into the
tumor and engineered to express hIL-12, a powerful cytokine that
has demonstrated the potential to stimulate a targeted, anti-tumor
immune response. The expression of hIL-12 is controlled and
modulated with the RheoSwitch Therapeutic System® (RTS®) by the
small molecule veledimex, an activator ligand which has been shown
to cross the blood brain barrier. ZIOPHARM anticipates initiation
of a pivotal trial for Ad-RTS-hIL-12 plus veledimex for the
treatment of rGBM by the end of 2017. The Company also has
initiated a Phase 1 study to evaluate the stereotactic
administration of Ad-RTS-hIL-12 plus veledimex in adult patients
with rGBM, and plans to initiate enrollment of adult patients with
rGBM who will receive a single dose of Ad-RTS-hIL-12 plus veledimex
in combination with a checkpoint inhibitor targeting programmed
cell death protein 1 (PD-1) by the end of the year.
About ZIOPHARM Oncology,
Inc.
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing innovative gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn
on and off, and precisely modulate, gene expression in order to
improve therapeutic index. The Company's pipeline includes a number
of cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor
Statement:
This press release contains certain
forward-looking information about ZIOPHARM Oncology, Inc. that is
intended to be covered by the safe harbor for "forward-looking
statements" provided by the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the progress and timing of the
development of the Company's research and development programs. All
of such statements are subject to certain risks and uncertainties,
many of which are difficult to predict and generally beyond the
control of the Company, that could cause actual results to differ
materially from those expressed in, or implied by, the
forward-looking statements. These risks and uncertainties include,
but are not limited to: the Company's ability to finance its
operations and business initiatives and obtain funding for such
activities; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any
of other product candidates will advance further in the preclinical
research or clinical trial process and whether and when, if at all,
they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for
which indications; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the
Company's other therapeutic products it develops will be
successfully marketed if approved; the strength and enforceability
of the Company's intellectual property rights; competition from
other pharmaceutical and biotechnology companies; as well as other
risk factors contained in the Company's periodic and interim
reports filed from time to time with the Securities and Exchange
Commission, including but not limited to, the risks and
uncertainties set forth in the "Risk Factors" section of the
Company's Quarterly Report on Form 10-Q for the quarter ended June
30, 2017 and subsequent reports that the Company may file with the
Securities and Exchange Commission. Readers are cautioned not to
place undue reliance on these forward-looking statements that speak
only as of the date hereof, and the Company does not undertake any
obligation to revise and disseminate forward-looking statements to
reflect events or circumstances after the date hereof, or to
reflect the occurrence of or non-occurrence of any events.
Trademarks
RheoSwitch Therapeutic System® and RTS® are
registered trademarks of Intrexon Corporation.
Contact:David ConnollyZIOPHARM
Oncology617-502-1881dconnolly@ziopharm.com
David PittsArgot
Partners212-600-1902david@argotpartners.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Sep 2023 to Sep 2024